➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Boehringer Ingelheim
Colorcon
Mallinckrodt

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Trastuzumab - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for trastuzumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Alabama at BirminghamPhase 1
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 3
Fundacion Clinic per a la Recerca BiomédicaPhase 2

See all trastuzumab clinical trials

Recent Litigation for trastuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.2019-03-29

See all trastuzumab litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-03-20
2018-01-08

See all trastuzumab litigation

Pharmacology for trastuzumab
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

Patent Text Search: US Patents for trastuzumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for trastuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013000157 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB EMTANSINE; REGISTRATION NO/DATE: EU/1/13/885 20131115
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2017000015 Germany   Start Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
2013 00063 Denmark   Start Trial PRODUCT NAME: TRASTUZUMABEMTANSIN; REG. NO/DATE: EU/1/13/885 20131119
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
Medtronic
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.